Investment Thesis
Turn Therapeutics is a pre-revenue pharmaceutical company with severe liquidity constraints and limited runway. With only $4.0M in cash and negative operating cash flow of -$2.6M annually, the company faces critical funding pressure within approximately 18 months. Financial metrics deteriorated sharply (net income down 80.6% YoY) with a current ratio of 0.87x indicating current liabilities exceed current assets.
Strengths
- Zero debt outstanding eliminates leverage and bankruptcy risk from leverage
- Remaining cash reserves of $4.0M provide near-term operational buffer
- Insider activity (5 Form 4 filings in 90 days) indicates management engagement
Risks
- No revenue generation; company remains in pre-revenue stage with no commercial products
- Negative operating cash flow of -$2.6M with only 18-month runway at current burn rate
- Liquidity crisis: current ratio of 0.87x means current liabilities exceed current assets
- Net income deteriorated 80.6% year-over-year indicating accelerating losses
- Minimal asset base ($12.2M total) provides limited financial flexibility
Key Metrics to Watch
- Monthly operating cash burn rate and remaining cash runway
- Clinical trial outcomes and regulatory milestone achievements
- Equity fundraising announcements and dilution impact
Financial Metrics
Revenue
N/A
Net Income
-3.2M
EPS (Diluted)
$-0.12
Free Cash Flow
-2.6M
Total Assets
12.2M
Cash
4.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-68.2%
ROA
-26.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.87x
Quick Ratio
0.87x
Debt/Equity
0.00x
Debt/Assets
61.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T22:57:27.174885 |
Data as of: 2025-12-31 |
Powered by Claude AI